Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia
作者: Lucia Beltran-CamachoMargarita Jimenez-PalomaresMarta Rojas-TorresIsmael Sanchez-GomarAntonio Rosal-VelaSara Eslava-AlconMª Carmen Perez-SeguraAna SerranoBorja Antequera-GonzálezJose Angel Alonso-PiñeroAlmudena González-RoviraMª Jesús Extremera-GarcíaManuel Rodriguez-PiñeroRafael Moreno-LunaMartin Røssel LarsenMª Carmen Durán-Ruiz
作者单位: 1Biomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain
2Institute of Biomedical Research Cadiz (INIBICA), Cadiz, Spain
3Angiology & Vascular Surgery Unit, Hospital Universitario Puerta del Mar, Cádiz, Spain
4Laboratory of Neuroinflammation, Hospital Nacional de Paraplejicos, SESCAM, Toledo, Spain
5Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark
刊名: Stem Cell Research & Therapy, 2020, Vol.11 (22), pp.11294-11322
来源数据库: Springer Nature Journal
DOI: 10.1186/s13287-020-01591-0
关键词: Critical limb ischemiaCirculating angiogenic cellsProteomicsAngiogenesisArteriogenesis
英文摘要: Abstract(#br)Background(#br)Critical limb ischemia (CLI) constitutes the most aggressive form of peripheral arterial occlusive disease, characterized by the blockade of arteries supplying blood to the lower extremities, significantly diminishing oxygen and nutrient supply. CLI patients usually undergo amputation of fingers, feet, or extremities, with a high risk of mortality due to associated comorbidities. Circulating angiogenic cells (CACs), also known as early endothelial progenitor cells, constitute promising candidates for cell therapy in CLI due to their assigned vascular regenerative properties. Preclinical and clinical assays with CACs have shown promising results. A better understanding of how these cells participate in vascular regeneration would significantly help to potentiate...
全文获取路径: Springer Nature  (合作)
影响因子:3.652 (2012)